Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaSattva S. Neelapu, William Y. Go, Olalekan O. Oluwole et al.|New England Journal of Medicine|2017Cited by 6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trialFrederick L. Locke, Sattva S. Neelapu, Armin Ghobadi et al.|The Lancet Oncology|2018Cited by 2.3k
Macro- and microscale variables regulate stent haemodynamics, fibrin deposition and thrombomodulin expressionJuan M. Jiménez, Peter F. Davies, Varesh Prasad et al.|Journal of The Royal Society Interface|2014Cited by 57
Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1Sattva S. Neelapu, William Y. Go, Frederick L. Locke et al.|Blood|2016Cited by 51
Perioperative characteristics and management of liver transplantation for isolated methylmalonic acidemia—the largest experience in ChinaYizhou Jiang, Xiaojie Chen, Li‐Ying Sun et al.|HepatoBiliary Surgery and Nutrition|2019Cited by 26